<DOC>
	<DOC>NCT00283478</DOC>
	<brief_summary>To determine if Iscar Quercus improves immune function and quality of life among patients with stage IV non-small cell lung cancer.</brief_summary>
	<brief_title>Iscar for Second Line Treatment of Advanced Non-Small Cell Lung Cancer</brief_title>
	<detailed_description>RAndomized pilot study of supplemental Iscar in combination with Gemcitabine vs. Gemcitabine alone as second line treatment for advanced non-small cell lung cancer.</detailed_description>
	<mesh_term>Lung Neoplasms</mesh_term>
	<mesh_term>Carcinoma, Non-Small-Cell Lung</mesh_term>
	<mesh_term>Gemcitabine</mesh_term>
	<criteria>newly diagnosed IIIB and IV NSCLC who have failed one prior line of chemo Karnofsky score 60% or greater patients who will be treated with Gemcitabine</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>October 2007</verification_date>
	<keyword>Advanced stage</keyword>
	<keyword>Lung cancer</keyword>
</DOC>